Abraham Bautista-Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abraham Bautista-Castillo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Angela Chun
Division of Rheumatology, Baylor College of Medicine, 1102 Bates, Ste. 330, Houston, 77030, TX, USA; Department of Pediatrics, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, USA
2 shared publications- Ioannis A. Kakadiaris
Department of Computer Science, University of Houston, Houston, TX 77204, USA
2 shared publications - Tiphanie P. Vogel
Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Center for Human Immunobiology, Texas Children's Research Institute, Texas Children's Hospital
2 shared publications Angela Christine Chun
Baylor College of Medicine
1 shared publicationEyal Muscal
Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital , Houston, Texas
1 shared publication- Flor Muñoz Rivas
Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
1 shared publication
Latest Publications
- 22 February 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 188, 109815
AI-MET: A deep learning-based clinical decision support system for distinguishing multisystem inflammatory syndrome in children from endemic typhus
- 22 February 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 188, 109815
AI-MET: A deep learning-based clinical decision support system for distinguishing multisystem inflammatory syndrome in children from endemic typhus
- 7 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 931-939
Distinguishing Multisystem Inflammatory Syndrome in Children From Typhus Using Artificial Intelligence: MIS-C Versus Endemic Typhus (AI-MET)
Background: The pandemic emergent disease multisystem inflammatory syndrome in children (MIS-C) following coronavirus disease-19 infection can mimic endemic typhus. We aimed to use artificial intelligence (AI) to develop a clinical decision support system that accurately distinguishes MIS-C versus endemic typhus (MET). Methods: Demographic, clinical, and laboratory features rapidly available following presentation were extracted for 133 patients with MIS-C and 87 patients hospitalized due to typhus. An attention module assigned importance to inputs used to create the 2-phase AI-MET. Phase 1 uses 17 features to arrive at a classification manually (MET-17). If the confidence level is not surpassed, 13 additional features are added to calculate MET-30 using a recurrent neural network. Results: While 24 of 30 features differed statistically, the values overlapped sufficiently that the features were clinically irrelevant distinguishers as individual parameters. However, AI-MET successfully classified typhus and MIS-C with 100% accuracy. A validation cohort of 111 additional patients with MIS-C was classified with 99% accuracy. Conclusions: Artificial intelligence can successfully distinguish MIS-C from typhus using rapidly available features. This decision support system will be a valuable tool for front-line providers facing the difficulty of diagnosing a febrile child in endemic areas.
- 7 January 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 931-939
Distinguishing Multisystem Inflammatory Syndrome in Children From Typhus Using Artificial Intelligence: MIS-C Versus Endemic Typhus (AI-MET)
Background: The pandemic emergent disease multisystem inflammatory syndrome in children (MIS-C) following coronavirus disease-19 infection can mimic endemic typhus. We aimed to use artificial intelligence (AI) to develop a clinical decision support system that accurately distinguishes MIS-C versus endemic typhus (MET). Methods: Demographic, clinical, and laboratory features rapidly available following presentation were extracted for 133 patients with MIS-C and 87 patients hospitalized due to typhus. An attention module assigned importance to inputs used to create the 2-phase AI-MET. Phase 1 uses 17 features to arrive at a classification manually (MET-17). If the confidence level is not surpassed, 13 additional features are added to calculate MET-30 using a recurrent neural network. Results: While 24 of 30 features differed statistically, the values overlapped sufficiently that the features were clinically irrelevant distinguishers as individual parameters. However, AI-MET successfully classified typhus and MIS-C with 100% accuracy. A validation cohort of 111 additional patients with MIS-C was classified with 99% accuracy. Conclusions: Artificial intelligence can successfully distinguish MIS-C from typhus using rapidly available features. This decision support system will be a valuable tool for front-line providers facing the difficulty of diagnosing a febrile child in endemic areas.
- Open Access
AI-MET: A Deep Learning-based Clinical Decision Support System for Distinguishing Multisystem Inflammatory Syndrome in Children from Endemic Typhus
A bstract: The COVID-19 pandemic brought several diagnostic challenges, including the post-infectious sequelae multisystem inflammatory syndrome in children (MIS-C). Some of the clinical features of this syndrome can be found in other pathologies such as Kawasaki disease, toxic shock syndrome, and endemic typhus. Endemic typhus, or murine typhus, is an acute infection treated much differently than MIS-C, so early detection is crucial to a favorable prognosis for patients with these disorders. Clinical Decision Support Systems (CDSS) are computer systems designed to support the decision-making of medical teams about their patients and intended to improve uprising clinical challenges in healthcare. In this article, we present a CDSS to distinguish between MIS-C and typhus that includes a scoring system that allows the timely distinction of both pathologies only using clinical and laboratory features typically available within the first six hours of presentation to the Emergency Department (ED). The proposed approach was trained and tested on datasets of 87 typhus patients and 133 MIS-C patients. A comparison was made against five well-known statistical and machine-learning models. A second dataset with 111 MIS-C patients was used to verify the AI-MET effectiveness and robustness. The performance assessment for AI-MET and the five statistical and machine learning models was done by computing Sensitivity, Specificity, Accuracy, and Precision. The AI-MET system scores 100 percent in the five metrics used on the training and testing dataset and 99 percent on the validation dataset.
Open AccessAI-MET: A Deep Learning-based Clinical Decision Support System for Distinguishing Multisystem Inflammatory Syndrome in Children from Endemic Typhus
A bstract: The COVID-19 pandemic brought several diagnostic challenges, including the post-infectious sequelae multisystem inflammatory syndrome in children (MIS-C). Some of the clinical features of this syndrome can be found in other pathologies such as Kawasaki disease, toxic shock syndrome, and endemic typhus. Endemic typhus, or murine typhus, is an acute infection treated much differently than MIS-C, so early detection is crucial to a favorable prognosis for patients with these disorders. Clinical Decision Support Systems (CDSS) are computer systems designed to support the decision-making of medical teams about their patients and intended to improve uprising clinical challenges in healthcare. In this article, we present a CDSS to distinguish between MIS-C and typhus that includes a scoring system that allows the timely distinction of both pathologies only using clinical and laboratory features typically available within the first six hours of presentation to the Emergency Department (ED). The proposed approach was trained and tested on datasets of 87 typhus patients and 133 MIS-C patients. A comparison was made against five well-known statistical and machine-learning models. A second dataset with 111 MIS-C patients was used to verify the AI-MET effectiveness and robustness. The performance assessment for AI-MET and the five statistical and machine learning models was done by computing Sensitivity, Specificity, Accuracy, and Precision. The AI-MET system scores 100 percent in the five metrics used on the training and testing dataset and 99 percent on the validation dataset.